Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

NCT00948922 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.

Details

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	PHASE2
Status	COMPLETED
Enrolment	124
Start date	Thu Jun 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Myeloma

Interventions

• Bortezomib
• Melphalan
• Autologous Stem Cell Transplant
• Fludarabine
• Allogeneic Stem Cell Transplant

Countries

United States